ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy.
作者信息
Omiya Kojiro, Oba Atsushi, Sugiura Kota, Maekawa Aya, Mie Takafumi, Kobayashi Kosuke, Ono Yoshihiro, Ito Hiromichi, Inoue Yosuke, Takahashi Yu
机构信息
Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
出版信息
Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17458-8.
PMID:40397341
Abstract
摘要
Zotero 插件